Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Routine Whole Genome Sequencing Offers a More Comprehensive Assessment of IG/TCR Gene Rearrangements for MRD Targets in Acute Lymphoblastic Leukemia - Data from the First 62 Cases from the NHS England Genomic Medicine Service

Stuart Adams, Jeremy Hancock, Joe Kaplinsky, Alona Sosinsky, Gary Wright, Soragia Athina Gkazi, Susanne Kricke, Rebecca Thomas, Natalie Kent, Angus Hodder, Jack Bartram

Blood (2023) 142 (Supplement 1): 4351.

https://doi.org/10.1182/blood-2023-187667

Published: 2023

Journal Articles

The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

David O'Connor, Jonas Demeulemeester, Lucia Conde, Amy A. Kirkwood, Kent Fung, Foteini Papaleonidopoulou, Gianna Bloye, Nadine Farah, Sunniyat Rahman, Jeremy Hancock, Caroline Bateman, Sarah Inglott, Jon Mee, Javier Herrero, Peter Van Loo, Anthony V. Moorman, Ajay Vora, Marc R. Mansour

Blood (2022) 140 (Supplement 1): 1720–1721.

https://doi.org/10.1182/blood-2022-165308

Published: 2022

Journal Articles

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Blood (2020) 135 (17): 1438–1446.

https://doi.org/10.1182/blood.2019003191

Published: 2020

Includes: Supplemental data

Journal Articles

Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL)

Anthony V. Moorman, PhD, Amir Enshaei, PhD, David O'Connor, MD PhD, Jack Bartram, MD, Jeremy Hancock, PhD, Christine Harrison, Sujith Samarasinghe, MD PhD, John Moppett, MD PhD, Ajay J. Vora, Nicholas Goulden, MD PhD

Blood (2016) 128 (22): 603.

https://doi.org/10.1182/blood.V128.22.603.603

Published: 2016

Journal Articles

Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:Â Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003

Jack Bartram, MD, David O'Connor, MD PhD, Amir Enshaei, PhD, Anthony V Moorman, PhD, Christine Harrison, PhDFRCPath FMedSci, Rachel Wade, MSc, Rachel Clack, MSc, Jeremy Hancock, PhD, Sujith Samarasinghe, MD PhD, John Moppett, MD PhD, Ajay J. Vora, Nicholas Goulden, MD PhD

Blood (2015) 126 (23): 806.

https://doi.org/10.1182/blood.V126.23.806.806

Published: 2015

Journal Articles

Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy

Amir Enshaei, PhD, Claire Schwab, Lucy Chilton, PhD, Rachel Wade, MSc, Jeremy Hancock, PhD, Christopher Mitchell, MBBS, PhD FRCP, Sally E Kinsey, Nicholas Goulden, MD PhD, Ajay J. Vora, Christine Harrison, PhDFRCPath FMedSci, Anthony V. Moorman, PhD

Blood (2015) 126 (23): 805.

https://doi.org/10.1182/blood.V126.23.805.805

Published: 2015

Journal Articles

Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms

Blood (2015) 126 (23): 1411.

https://doi.org/10.1182/blood.V126.23.1411.1411

Published: 2015

Journal Articles

Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial

David O'Connor, MD PhD, Jack Bartram, MD, Amir Enshaei, PhD, Anthony V Moorman, PhD, Christine Harrison, PhDFRCPath FMedSci, Rachel Wade, MSc, Rachel Clack, MSc, Jeremy Hancock, PhD, Sujith Samarasinghe, MD PhD, John Moppett, MD PhD, Ajay J. Vora, Nicholas Goulden, MD PhD

Blood (2015) 126 (23): 1412.

https://doi.org/10.1182/blood.V126.23.1412.1412

Published: 2015

Journal Articles

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Blood (2015) 126 (23): 1414.

https://doi.org/10.1182/blood.V126.23.1414.1414

Published: 2015

Journal Articles

Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

Catriona Anne Parker, PhD, Marie Reeves, MSc, Sharon Love, MSc, Jeremy Hancock, PhD, Peter M Hoogerbrugge, MD PhD, Rosemary Sutton, Tom Revesz, MD, Vaskar Saha, PhD FRCP, FRCPath

Blood (2015) 126 (23): 1294.

https://doi.org/10.1182/blood.V126.23.1294.1294

Published: 2015

Journal Articles

No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial

Sarah Jenkinson, MSc, Amy A Kirkwood, Nicholas Goulden, MD PhD, Ajay J. Vora, Chris Mitchell, Rachel Wade, Jeremy Hancock, Anthony V. Moorman, PhD, David C Linch, FMedSci, Rosemary E Gale

Blood (2014) 124 (21): 1077.

https://doi.org/10.1182/blood.V124.21.1077.1077

Published: 2014

Journal Articles

Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study

Blood (2014) 124 (21): 3782.

https://doi.org/10.1182/blood.V124.21.3782.3782

Published: 2014

Journal Articles

Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial

Katharine Patrick, Rachel Wade, Nicholas Goulden, MD PhD, Chris Mitchell, Clare Rowntree, FRCPath, Jeremy Hancock, Rachael E Hough, MD, Ajay J. Vora, FRCPath

Blood (2014) 124 (21): 3702.

https://doi.org/10.1182/blood.V124.21.3702.3702

Published: 2014

Journal Articles

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia

Anthony V. Moorman, Amir Enshaei, Claire Schwab, Rachel Wade, Lucy Chilton, Alannah Elliott, Stacey Richardson, Jeremy Hancock, Sally E. Kinsey, Christopher D. Mitchell, Nicholas Goulden, Ajay Vora, Christine J. Harrison

Blood (2014) 124 (9): 1434–1444.

https://doi.org/10.1182/blood-2014-03-562918

Published: 2014

Includes: Supplemental data

Journal Articles

Development Of Minimal Residual Disease (MRD) Analysis In Childhood Acute Lymphoblastic Leukaemia (ALL) By Next Generation Sequencing (NGS)

Helen Williamson, Edward Mountjoy, Hashem Shihab, Jack Bartram, Mike Hubank, Nicholas Goulden, Ian Day, Eileen Roberts, John Moppett, Jeremy Hancock

Blood (2013) 122 (21): 2569.

https://doi.org/10.1182/blood.V122.21.2569.2569

Published: 2013

Journal Articles

Excellent Outcome Of MRD Low Risk Patients Is Sustained With Greater Than 10 Years Follow Up – Results Of UK ALL Trials 1997 -2003

Jack Bartram, Rachel Clack, Rachel Wade, Ajay J Vora, Jeremy Hancock, Chris Mitchell, Sally Kinsey, Colin Steward, John P Moppett, MD, PhD, Nicholas Goulden

Blood (2013) 122 (21): 2635.

https://doi.org/10.1182/blood.V122.21.2635.2635

Published: 2013

Journal Articles

Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study

Giovanni Cazzaniga, Martin Schrappe, Paola de Lorenzo, Anders Castor, Giovanna Lucchini, Virginie Gandemer, Rob Pieters, MD, PhD, Jan Stary, Gabriele Escherich, Jeremy Hancock, Maurizio Arico', Silja Röttgers, Vaskar Saha, Andrea Biondi, MD, Maria Grazia Valsecchi

Blood (2012) 120 (21): 1467.

https://doi.org/10.1182/blood.V120.21.1467.1467

Published: 2012

Journal Articles

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Caroline YK Fong, Catriona Anne Parker, Adiba Hussain, Jizhong Liu, Monika Essink, Hans Juergen Kuehnel, Donna L Lancaster, Genevieve Pridham, Debbie Payne, Charlotte O'Horo, Shekhar Krishnan, Jeremy Hancock, Nicholas Goulden, Anthony V. Moorman, Sue Richards, Ajay J Vora, Vaskar Saha, Ashish Narayan Masurekar

Blood (2011) 118 (21): 2573.

https://doi.org/10.1182/blood.V118.21.2573.2573

Published: 2011

Journal Articles

Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study

Ashish Narayan Masurekar, Catriona Anne Parker, BSc, MSc, PhD, Satarupa Choudhuri, Carly Leighton, Jeremy Hancock, Rosemary Sutton, Anthony V. Moorman, PhD, Phil Ancliff, Mary Morgan, MD, Nicholas Goulden, Nina Green, Tamas Revesz, MD, PhD, FRACP, Peter Hoogerbrugge, MD, PhD, Philip Darbyshire, Sharon Love, Vaskar Saha

Blood (2010) 116 (21): 3303.

https://doi.org/10.1182/blood.V116.21.3303.3303

Published: 2010

Journal Articles

Mitoxantrone, Not Idarubicin, Significantly Improves the Outcome of Children with Relapsed ALL – Result of the International, Randomised ALLR3 Study.

Catriona Parker, Rachel Waters, Carly Leighton, Jeremy Hancock, Anthony Moorman, Mary Morgan, Philip Ancliff, Nicholas Goulden, Rosemary Sutton, Tamas Revesz, Philip Darbyshire, Sharon Love, Vaskar Saha

Blood (2009) 114 (22): 3390.

https://doi.org/10.1182/blood.V114.22.3390.3390

Published: 2009

NARROW

Routine Whole Genome Sequencing Offers a More Comprehensive Assessment of IG/TCR Gene Rearrangements for MRD Targets in Acute Lymphoblastic Leukemia - Data from the First 62 Cases from the NHS England Genomic Medicine Service

The Clinico-Genomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia

Integrating Genetic Risk Factors with Age, Presenting White Cell Count and MRD Response As Continuous Variables to Predict Relapse in Paediatric Acute Lymphoblastic Leukemia (ALL)

Long Term Overall Survival of Greater Than 98% in Childhood ALL Patients with Good Risk Features and Low Risk MRD:Â Results from a Large Multi-Center Randomized Controlled Trial, UKALL 2003

Risk Factor Analysis in Paediatric Acute Lymphoblastic Leukaemia with High Hyperdiploidy

Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms

Integration of Minimal Residual Disease with Other Patient Risk Factors Identifies a Population with Very Poor Overall Survival in Pediatric ALL: Results from the UKALL 2003 Trial

Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol

Post Induction Minimal Residual Disease Levels Identifies a Group of High Risk Relapsed Childhood Acute Lymphoblastic Leukemia (rALL) with a Favorable Outcome Independent of Induction Therapy

No Evidence That PTEN Abnormalities Impact on Outcome in Pediatric Patients with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated on the MRC UKALL2003 Trial

Comparison of MRD Monitoring By IG/TR Rearrangement and BCR/ABL1 Transcript in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with Imatinib in the Esphall Study

Improved Outcome for Children and Young People with T-Acute Lymphoblastic Leukaemia: Results of the UKALL 2003 Trial

A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia

Development Of Minimal Residual Disease (MRD) Analysis In Childhood Acute Lymphoblastic Leukaemia (ALL) By Next Generation Sequencing (NGS)

Excellent Outcome Of MRD Low Risk Patients Is Sustained With Greater Than 10 Years Follow Up – Results Of UK ALL Trials 1997 -2003

Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study

Intramuscular PEG-Asparaginase At 1000 U/m 2 Achieves Adequate Trough Activity Levels in the Majority of Patients Treated on the UKALL 2003 Childhood Acute Lymphoblastic Leukemia (ALL) Protocol

Mitoxantrone Improves the Outcome of Children with Central Nervous System (CNS) Involvement at First Relapse of Acute Lymphoblastic Leukemia (ALL)-Results of the International ALLR3 Study

Mitoxantrone, Not Idarubicin, Significantly Improves the Outcome of Children with Relapsed ALL – Result of the International, Randomised ALLR3 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only